3RD-GENERATION CHEMOTHERAPY WITH P-VABEC FOR AGGRESSIVE NON-HODGKINS-LYMPHOMAS OF THE ELDERLY

被引：14

作者：

CARACCIOLO, F

PETRINI, M

CAPOCHIANI, E

PAPINESCHI, F

GRASSI, B

机构：

[1] Hematology Unit, Medical Clinic, University of Pisa, Ospedale Santa Chiara, Pisa

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷 / 1-2期

关键词：

NON-HODGKINS LYMPHOMA; CHEMOTHERAPY; ELDERLY;

D O I：

10.3109/10428199309054738

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Between July 1990 and March 1992, 23 elderly patients with intermediate or high-grade non-Hodgkin's lymphomas (NHL) received a combination chemotherapy (P-VABEC: Etoposide, Adriamicin and Cyclophosphamide on days 1, 15, 29, 43, Vincristine and Bleomycin on days 8, 22, 36, 50 and Prednisolone on weeks 1-9). The regimen was administered on an outpatient basis. The median age of the patients was 67 years (range 60-78); 15 were previously untreated, 8 were on second line therapy; 6 patients (44%) had stage IV disease, 19 (83%) B symptoms, 15 (65%) had bulky disease, and (26%) bone marrow involvement. The complete remission (CR) rate was 57%, and the partial remission (PR) rate 43%, with an overall response rate of (100%). No difference in response rate was observed between previously untreated patients and patients treated with P-VABEC as second-line therapy while hematological and clinical toxicity were very mild.

引用

页码：115 / 118

页数：4

共 28 条

[1] McKelvey E.M., Gottlieb J.A., Wilson H.E., Et al., Hydroxyldaunomicin (Adriamycin) combination chemotherapy in malignant lymphoma, Cancer, 38, pp. 11484-11493, (1976)
[2] Skarin A.T., Canellos G.P., Rosenthal D.S., Case D.C., Macintyre J.M., Pinkus G.S., Moloney W.C., Frei E., Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by the use of high dose metho-trexate alternating with standard agents (M-BACOD), J. Clin. Oncnl., 1, (1983)
[3] Armitage J.O., Potter J.F., Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age, J. Am. Geriatr. Soc., 32, pp. 269-273, (1984)
[4] Fisher R.I., De Vita V.T., Hubbard S.M., Longo D.L., Wesley R., Chabner B.A., Young R.C., Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy, Ann. Inter. Med., 98, pp. 304-309, (1983)
[5] Fisher R.I., Longo D.L., De Vita V.T., Hubbard S.M., Miller T.P., Young R.C., Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas, Ann. Oncol., 2, pp. 33-35, (1991)
[6] Longo D.L., De Vita V.T., Duffey P.L., Wesley M.N., Ihde D.C., Hubbard S.M., Gilliom M., Jaffe E.S., Cossman J., Fisher R.I., Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial, J. Clin. Oncol., 9, pp. 25-38, (1991)
[7] O'Reilly S.E., Connors J.M., Klimo P., Low dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma, J. CIin. Oncol., 9, pp. 741-742, (1991)
[8] Schneider A.M., Straus D.J., Schugler A.E., Lowenthal D.A., Koriner B., Lee B.J., Womg G., Clarkson B.D., Treatment result with an aggressive chemo-therapeutic regimen (MACOP-B) for intermediate and some high-grade non Hodgkin's lymphomas, 1. Clin. Oncol., 8, pp. 94-102, (1990)
[9] Guglielmi C., Amadori S., Martelli M., Papa G., Mandelli F., The F-MACHOP regimen in advanced diffuse aggressive lymphomas: summary of ten years' experience at a single institution, Leukemia., 5, pp. 102-104, (1991)
[10] Goldie J.H., Goldman A.J., Gudauskas G.A., Rationale for the use of alternating non-cross resistant chemotherapy, Cancer Treat. Rep., 66, (1982)

← 1 2 3 →